Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2018. Available from: https://www.ginasthma.org. Accessed November 16, 2018.
   Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children (Review). Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• Asthma. Statistics Canada; 2015. Available from: https://www150.statcan.gc.ca/n1/pub/82-625-x/2015001/article/14179-eng.htm. Accessed November 16, 2018..
   Google Scholar
• Health indicators, annual estimates, 2003–2014. Statistics Canada; 2018. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310045101. Accessed November 26, 2018.
   Google Scholar
• Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Resp J. 2012;19:127–164.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Lemiere C, Lougheed MD, et al. Recognition and management of severe asthma: a Canadian Thoracic Society position statement. Can J Resp Crit Care Sleep Med. 2017;1:199–221.
   Google Scholar
• Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. doi:10.1186/1471-2466-9-24
   PubMedGoogle Scholar
• Ehteshami-Afshar S, FitzGerald JM, Doyle-Waaters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20:11–23. doi:10.5588/ijtld.15.0472
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 2012;129:48–59. doi:10.1016/j.jaci.2011.11.006
   PubMed Web of Science ®Google Scholar
• Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Resp Pulm Med. 2012;6:27–40.
   PubMedGoogle Scholar
• ENFUMOSA (European Network for Understanding Mechanisms of Severe Asthma). The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003;22:470–477. doi:10.1183/09031936.03.00261903
   Web of Science ®Google Scholar
• Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18:693–704. doi:10.1038/nm.2755
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958–972. doi:10.1038/nrd3792
   PubMed Web of Science ®Google Scholar
• Product Monograph: Xolair® (omalizumab). Novartis Pharmaceutics Canada Inc.; 2017. Available from: https://www.novartis.ca/sites/www.novartis.ca/files/xolair_scrip_e.pdf. Accessed November 16, 2018.
   Google Scholar
• Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM; on behalf of the British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax. 2010;65:787–794. doi:10.1136/thx.2010.137414
   PubMed Web of Science ®Google Scholar
• Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66:910–917. doi:10.1136/thx.2010.153643
   PubMed Web of Science ®Google Scholar
• Bhutani M, Yang WH, Hebert J, de Takacsy F, Stril J-L. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. PLoS One. 2017;12:e0183869. doi:10.1371/journal.pone.0183869
   PubMed Web of Science ®Google Scholar
• Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan. Respir Med. 2018;141:56–63. doi:10.1016/j.rmed.2018.06.021
   PubMed Web of Science ®Google Scholar
• Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012;49:78–82. doi:10.3109/02770903.2011.637598
   PubMed Web of Science ®Google Scholar
• Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of Omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50:529–536. doi:10.3109/02770903.2013.790419
   PubMed Web of Science ®Google Scholar
• Braunstahl G-J, Chlumsky J, Peachey G, Maykut R, Chen C-W. Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting. Clin Translat Allergy. 2013;3(Suppl 1):P13. doi:10.1186/2045-7022-3-S1-P13
   Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103:1633–1642. doi:10.1016/j.rmed.2009.06.014
   PubMed Web of Science ®Google Scholar
• Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103:1725–1731. doi:10.1016/j.rmed.2009.05.002
   PubMed Web of Science ®Google Scholar
• Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104:1381–1385. doi:10.1016/j.rmed.2010.06.001
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Barbuto S, et al. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: results of a 5-year single-center observational study. Pulm Pharmacol Ther. 2019;54:25–30. doi:10.1016/j.pupt.2018.11.002
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012;25:77–82. doi:10.1016/j.pupt.2011.11.004
   PubMed Web of Science ®Google Scholar
• Vennera MD, Llano De LP, Bardagi S, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry—Some new approaches. J Asthma. 2012;49:416–422. doi:10.3109/02770903.2012.668255
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71:593–610. doi:10.1111/all.12815
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9:343–350. doi:10.5489/cuaj.3098
   PubMed Web of Science ®Google Scholar
• Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017;7:e015872. doi:10.1136/bmjopen-2017-015872
   PubMed Web of Science ®Google Scholar
• Blais A-S, Bergeron M, Nadeau G, Ramsay S, Bolduc S. Anticholinergic use in children: persistence and patterns of therapy. Can Urol Assoc J. 2016;10:137–140. doi:10.5489/cuaj.3527
   PubMed Web of Science ®Google Scholar
• Husereau D, Goodfield J, Leigh R, Borrelli R, Cloutier M, Gendron A. Severe, eosinophilic asthma in primary care in Canada: longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy Asthma Clin Immunol. 2018;14:15. doi:10.1186/s13223-018-0241-1
   Web of Science ®Google Scholar
• Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006;118:899–904. doi:10.1016/j.jaci.2006.07.002
   PubMed Web of Science ®Google Scholar
• Ke X, Kavati A, Wertz D, et al. Real-world clinical characteristics, treatment patterns, and exacerbations in US patients with asthma newly treated with Omalizumab. Clin Ther. 2018;40:1140–1158. doi:10.1016/j.clinthera.2018.05.014
   Web of Science ®Google Scholar
• Chen H, Eisner MD, Haselkorn T, Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med. 2013;107:60–67. doi:10.1016/j.rmed.2012.09.008
   PubMed Web of Science ®Google Scholar
• Zein JG, Erzurum SC. Asthma is different in women. Curr Allergy Asthma Rep. 2015;15:28. doi:10.1007/s11882-015-0528-y
   PubMed Web of Science ®Google Scholar
• Almqvist C, Worm M, Leynaert B. working group of GA2LEN WP 2.5 gender. Impact of gender on asthma in childhood and adolescence: a GA2LEN review. Allergy. 2008;63:47–57. doi:10.1111/j.1398-9995.2007.01524.x
   PubMed Web of Science ®Google Scholar
• Vink NM, Postma DS, Schouten JP, Rosmalen JGM, Boezen HM. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents’ Individual Lives Survey (TRAILS) study. J Allergy Clin Immunol. 2010;126(3):498–504. doi:10.1016/j.jaci.2010.06.018
   PubMed Web of Science ®Google Scholar
• Melgert BN, Ray A, Hylkema MN, Timens W, Postma DS. Are there reasons why adult asthma is more common in females? Curr Allergy Asthma Rep. 2007;7:143–150. doi:10.1007/s11882-007-0012-4
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140:162–169. doi:10.1016/j.jaci.2016.08.054
   PubMed Web of Science ®Google Scholar
• Molimard M, Mala L, Bourdeix I, Le Gros V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014;108:571–576. doi:10.1016/j.rmed.2014.02.003
   PubMed Web of Science ®Google Scholar
• del Carmen Vennera M, Sabadell C, Picado C, et al. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018;73:782–784. doi:10.1136/thoraxjnl-2017-210017
   Web of Science ®Google Scholar